

Amendments to the Claims

Please amend claims 3-7, 9, 10, 12, 14, 15, 18-23, 26, 28 and 30 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) An adhesive patch suitable for the transdermal administration of granisetron, wherein the adhesive is an acrylic adhesive containing non-acidic hydroxyl moieties, a physiologically effective amount of granisetron being loaded in the adhesive.
2. (Previously presented) A patch according to claim 1, wherein the non-acidic hydroxyl moieties are provided by suitably selected comonomers.
3. (Currently amended) A patch according to claim 2, wherein the selected comonomers are selected from **the group consisting of** substituted acrylates and **substituted** methacrylates.
4. (Currently amended) A patch according to claim 3, wherein the acrylate is selected from the **group consisting of** hydroxymethyl **acrylates**, hydroxyethyl **acrylates** and hydroxypropyl acrylates.
5. (Currently amended) A patch according to claim 3, wherein the methacrylate is selected from the **group consisting of** hydroxymethyl **methacrylates** and hydroxyethyl methacrylates.
6. (Currently amended) A patch according to **any preceding** claim **1**, which is pressure sensitive.
7. (Currently amended) A patch according to **any preceding** claim **1**, containing a major amount of a primary acrylate monomer.
8. (Original) A patch according to claim 7, wherein the primary acrylate monomer is either 2-ethylhexyl acrylate or butyl acrylate.

9. (Currently amended) A patch according to ~~any preceding~~ claim 1, adapted to provide a pharmacologically effective amount of granisetron after about 2 hours.
10. (Currently amended) A patch according to ~~any preceding~~ claim 1, comprising up to about 10% by weight of granisetron.
11. (Previously presented) A patch according to claim 10, having less than 8% w/w granisetron.
12. (Currently amended) A patch according to ~~any preceding~~ claim 1, having a level of granisetron above 4% w/w.
13. (Previously presented) A patch according to claim 10, having a level of between 6% and 7.7% w/w of granisetron.
14. (Currently amended) A patch according to ~~any preceding~~ claim 1, wherein no crystallisation is observed after one month storage at room temperature and pressure.
15. (Currently amended) A patch according to ~~any preceding~~ claim 1, for the treatment of chemically induced emesis.
16. (Previously presented) A patch according to claim 15, wherein the emesis is acute.
17. (Previously presented) A patch according to claim 15, wherein the emesis is delayed.
18. (Currently amended) A patch according to ~~any of~~ claim[[s]] 1 to 14, for the treatment and/or prophylaxis of emesis associated with fractionated chemotherapy.
19. (Currently amended) A patch according to ~~any of~~ claim[[s]] 1 to 14, for the treatment and/or prophylaxis of postoperative nausea and vomiting.
20. (Currently amended) A patch according to ~~any of~~ claim[[s]] 1 to 14, for the treatment and/or prophylaxis of nausea and vomiting associated with radiotherapy.

21. (Currently amended) A patch according to ~~any of~~ claim[[s]] 1 ~~to 14~~, for the treatment and/or prophylaxis of nausea and vomiting associated with fractionated cancer therapy.

22. (Currently amended) A patch according to ~~any of~~ claim[[s]] 1 ~~to 14~~, for the treatment and/or prophylaxis of a condition selected from[[;]] the group consisting of: pruritus, fibromyalgia and pain associated therewith, migraine, anxiety, cognitive and psychotic disorders, depression, schizophrenia, psychosis in postnatal depression, irritable bowel syndrome, alcoholism, obstructive sleep disturbed breathing, motion sickness, loss of cognitive function ~~such as Alzheimer's~~, urinary incontinence, dyskinesia, systemic lupus erythematosus, drug-induced pruritus, premature ejaculation, eating disorders, obsessive compulsive disorder, gastric motility disorders, chronic fatigue syndrome, dyspepsia and cocaine dependence.

23. (Currently amended) A patch according to ~~any preceding~~ claim 1, wherein the adhesive is loaded with between 3 and 12% w/w granisetron.

24. (Previously presented) A patch according to claim 23, wherein the adhesive is loaded with between 4 and 10% w/w granisetron.

25. (Previously presented) A patch according to claim 23, wherein the adhesive is loaded with between 5 and 8% w/w granisetron.

26. (Currently amended) A patch according to ~~any preceding~~ claim 1, incorporating no plasticizers or permeation enhancers.

27. (Cancelled)

28. (Currently amended) A patch according to ~~any preceding~~ claim 1, wherein, at an adhesive loading of 6% w/w of active granisetron, the adhesive has a surface area of between 10 and 100 cm².

29. (Original) A patch according to claim 28, wherein the adhesive has a surface area of between 15 and 50 cm².

30. (Currently amended) A method for the treatment of a condition associated with 5-HT₃ receptor activity in a patient in need thereof, comprising administering an adhesive patch according to ~~any preceding~~ claim 1 to the skin of the patient.